AbbVie is trading at $273.07, a -4.32% move in after-hours trading; the cause remains unconfirmed.

  • No confirmed October 16 company announcement has been identified to explain the decline.
  • AbbVie had previously lowered its 2026 adjusted EPS outlook, but that earlier update does not establish a fresh catalyst.
  • The Nasdaq was down 2.12% and the S&P 500 down 1.09%; AbbVie’s regular-session close was up 0.71%.